Analysts Set Phreesia, Inc. (NYSE:PHR) Target Price at $29.42

Phreesia, Inc. (NYSE:PHR) has received an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $29.42.

A number of brokerages have weighed in on PHR. JPMorgan Chase & Co. upped their price target on Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reissued a “sector perform” rating and set a $23.00 price target on shares of Phreesia in a report on Friday, September 27th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $34.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Finally, Robert W. Baird raised their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, September 6th.

Insider Activity at Phreesia

In other news, General Counsel Allison C. Hoffman sold 2,622 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $60,961.50. Following the transaction, the general counsel now owns 123,075 shares of the company’s stock, valued at $2,861,493.75. This represents a 2.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Chaim Indig sold 5,295 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total value of $123,108.75. Following the completion of the transaction, the chief executive officer now owns 1,223,736 shares in the company, valued at approximately $28,451,862. This represents a 0.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,997 shares of company stock valued at $667,943 over the last quarter. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Several institutional investors have recently modified their holdings of PHR. International Assets Investment Management LLC boosted its stake in Phreesia by 2,179.7% in the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares during the last quarter. nVerses Capital LLC boosted its position in shares of Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after purchasing an additional 1,300 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Phreesia during the first quarter worth $202,000. Lombard Odier Asset Management USA Corp bought a new stake in Phreesia in the second quarter valued at about $202,000. Finally, Point72 DIFC Ltd acquired a new position in Phreesia in the second quarter valued at about $209,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Price Performance

Shares of Phreesia stock opened at $21.03 on Wednesday. The firm has a market cap of $1.21 billion, a P/E ratio of -11.68 and a beta of 0.94. The firm’s 50-day simple moving average is $20.43 and its 200-day simple moving average is $21.84. Phreesia has a twelve month low of $14.55 and a twelve month high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The company had revenue of $102.12 million for the quarter, compared to the consensus estimate of $101.76 million. As a group, research analysts expect that Phreesia will post -1.23 EPS for the current fiscal year.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.